Presidential Symposium

• 

  PS01 New Insights and Challenges in Managing Chronic GVHD Stephanie Lee Fred Hutch Cancer Center, USA CV

Plenary Session 1: State of the Art in Cell Therapy

• 

  PL01-1 Mesenchymal Stem Cell Therapy Katarina Le Blanc Karolinska Institutet, Sweden CV
• 

  PL01-2 Natural Killer Cell-Based Cancer Therapy Dan Kaufman University of California San Diego, USA CV

Plenary Session 2: Alternative Donors

• 

  PL02-1 How to Improve the Outcome of CBT Vanderson Rocha University of São Paulo, Brazil CV
• 

  PL02-1 Trends and Future of the HSCT Using Mismatched Donors Anna Sureda Catalan Institute of Oncology, Spain CV

Plenary Session 3: HSCT in Myeloid Diseases

• 

  PL03-1 Biology and Strategy to Prevent and Treat Post-HSCT Relapse in Myeloid Diseases John F. DiPersio Washington University in St. Louis, USA CV

Scientific Session 1: Dealing with Practical Issues of Transplantation in Aplastic Anemia

• 

  SS01-1 Optimal Strategy of Transplantation in Fanconi Anemia Jae Wook Lee The Catholic University of Korea, Korea CV
• 

  SS01-2 Choice of Appropriate Conditioning Regimens for Aplastic Anemia Nelli Bejanyan Moffitt Cancer Center, USA CV
• 

  SS01-3 Mutational Landscape of Severe Aplastic Anemia and Implications for Therapy William Hogan Mayo Clinic, USA CV

Scientific Session 2: Immunotherapy for Lymphoid Malignancy in the Post-CAR T Era

• 

  SS02-1 Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma Suzanne Trudel University of Toronto, Canada CV
• 

  SS02-2 Novel Immunotherapy for Relapsed and Refractory B-Cell Lymphomas Won Seog Kim Sungkyunkwan University School of Medicine, Korea CV
• 

  SS02-3 Best Positioning of Immunotherapy in Adult B-Cell ALL Mark R. Litzow Mayo Clinic, USA CV

Scientific Session 3: Transplantation Related Immunology

• 

  SS03-1 Immune Reconstitution after HSCT Stefan Nierkens Princess Máxima Center for Pediatric Oncology, Netherlands CV
• 

  SS03-2 Proteomics in HSCT Sophie Paczesny Medical University of South Carolina, USA CV
• 

  SS03-3 GVHD Immunology Geoffrey R. Hill Fred Hutchinson Cancer Center, USA CV

Scientific Session 4: Divergent Approaches to the Use of Autologous Hematopoietic Stem Cell Transplantation

• 

  SS04-1 NK Cells in Autologous Stem Cell Transplantation Hareth Nahi Karolinska Institutet, Sweden
• 

  SS04-2 Homology Directed Repair based Gene Editing (HDR-Editing): A Precise and Versatile Method to Engineer Hematopoietic Stem Cells to Treat Rare and Common Diseases Matthew H Porteus Stanford University, USA CV
• 

  SS04-3 Autologous Stem Cell Transplantation in Pediatric Solid Tumor: Clinical Benefit and Late Effect Ji Won Lee Sungkyunkwan University School of Medicine, Korea CV

Scientific Session 5: GVHD in 2023: From Prediction to Prevention

• 

  SS05-1 New Insights into the Pathophysiology of GVHD Takanori Teshima Hokkaido University, Japan CV
• 

  SS05-2 Predicting GVHD: From Biomarkers to Clinical Risk Score Margaret MacMillan University of Minnesota, USA CV
• 

  SS05-3 Post-Transplant Cyclophosphamide as the New Standard for GVHD Prophylaxis Byung-Su Kim The Catholic University of Korea, Korea CV

Scientific Session 6: New Insights in the Immune Effector Cell Therapies for Multiple Myeloma

• 

  SS06-1 Next Generation Immunotherapy in Multiple Myeloma Thomas Martin UCSF Medical Center, USA CV
• 

  SS06-2 Clinical Utility of CAR T-Cells in Earlier-Lines in Multiple Myeloma Saad Z Usmani Memorial Sloan Kettering Cancer Center, USA CV
• 

  SS06-3 Predictors of Response and Resistance of CAT-T or BsAb Therapy Yi Lin Mayo Clinic, USA CV
• 

  SS06-4 Prognostic Values of MRD Status after CAR-T or BsAb Therapies Bruno Paiva The University of Navarra, Spain CV

Scientific Session 7: Strategies for Successful Cord Blood Transplantation

• 

  SS07-1 Recent Update of Cord Blood Transplantation in Adult Dong-Yeop Shin Seoul National University College of Medicine, Korea CV
• 

  SS07-2 Experience of Cord Blood Transplantation in Japan Satoshi Takahashi The University of Tokyo, Japan CV
• 

  SS07-3 Experience of Cord Blood Transplantation in USA Filippo Milano Fred Hutchinson Cancer Center, USA CV
• 

  SS07-4 The Status of Cord Blood Banks (CBBs) for Unrelated Hematopoietic Stem Cell Transplantation (UR-HCT) & its Management of CBBs in Korea Jung Lim Lee Daegu Fatima Hospital, Korea CV

Scientific Session 8: Bone Marrow Microenvironment in Hematologic Malignancy

• 

  SS08-1 The Bone Marrow Microenvironment in Myeloid Leukemia Daniela Krause Goethe University Frankfurt, Germany CV
• 

  SS08-2 PDE4B is a Potential Therapeutic Target to Disrupt the Interplay between Lymphomas and the Bone Marrow Microenvironment Sang-Woo Kim Pusan National University, Korea CV
• 

  SS08-3 The Bone Marrow Microenvironment in Multiple Myeloma Yoon Seok Choi Ajou Universitry School of Medicine, Korea CV

Scientific Session 9: Finding New Era of Haploidentical HSCT

• 

  SS09-1 PTCY Alone vs. PTCY+ATG Combination in Haploidentical HSCT Hee Young Ju Sungkyunkwan University School of Medicine, Korea CV
• 

  SS09-2 Understanding How T and NK Cells Mediate the GVL Effect without GVHD in Haploidentical HSCT: Insights into Biological Mechanisms Loredana Ruggeri University of Perugia, Italy CV
• 

  SS09-3 Regimen Intensity and the Role of Total Body Irradiation in Haploidentical HSCT Jongheon Jung National Cancer Center, Korea CV

Scientific Session 10: Data to Clinic for Better Stem Cell Transplantation

• 

  SS10-1 Electronic Health Record Use for Hematopoietic Cell Transplantation Research Sung Won Choi University of Michigan, USA CV
• 

  SS10-2 Artificial Intelligence in Stem Cell Transplantation Shahrukh K. Hashmi Sheikh Shakhbout Medical City, UAE CV
• 

  SS10-3 Recent Advances in Artificial Intelligence in Healthcare Yoonjae Choi KAIST, Korea CV

Scientific Session 11: Pediatric Leukemia: Recent Advances in Treatments

• 

  SS11-1 Real World CAR-T in Pediatric Patients Theodore W. Laetsch The Children's Hospital of Philadelphia, USA CV
• 

  SS11-2 Pediatric Leukemia in the MRD Era (MRD Guided Treatment) Hiroto Inaba St. Jude Children's Research Hospital, USA CV
• 

  SS11-3 Hematopoietic Stem Cell Transplantation for Pediatric AML Daisuke Tomizawa National Center for Child Health and Development, Japan CV

Scientific Session 12: Optimizing HSCT Outcomes in Patients with High-Risk AML

• 

  SS12-1 The Role of MRD Monitoring and MRD-Directed Therapy in Patients with AML Jae-Sook Ahn Chonnam National University Medical School, Korea CV
• 

  SS12-2 Venetoclax Combination Therapy as a Bridging for HSCT in Elderly or Unfit AML Maximilian Stahl Dana-Farber Cancer Institute, USA CV
• 

  SS12-3 HSCT for Elderly Patients With AML or MDS: Geriatric Assessment and Transplant Decision Gi June Min The Catholic University of Korea, Korea CV

Scientific Session 13: Recent Advances in Cellular Immunotherapy

• 

  SS13-1 Tumor Microenvironment in CAR T-Cell Therapy Saad S. Kenderian Mayo Clinic, USA CV
• 

  SS13-2 Engineered T Cells Produced From “Alternative Cellular Sources” Hiroshi Kawamoto Kyoto University, Japan CV
• 

  SS13-3 TCR-T Cells for Cancer Premal D. Lulla Baylor College of Medicine, USA CV
• 

  SS13-4 Revolutionizing Solid Tumor Immunotherapy with CAR-NK Cells Mihue Jang KIST, Korea CV

Joint Symposium 1 (ASTCT-KSBMT): Is HSCT still Relevant in Immunotherapy Era for Lymphoid Malignancies?

• 

  JS01-1 Cell Therapies for Lymphoid Malignancies Hyunsoo Cho Yonsei University College of Medicine, Korea CV
• 

  JS01-2 Pediatrics Perspective Rayne Rouce Baylor College of Medicine, USA CV
• 

  JS01-3 Stem Cell Transplant Julie Vose University of Nebraska Medical Center, USA CV

Joint Symposium 2 (TSBMT-KSBMT): Experiences and Future Perspectives on Transplantation and Cellular Therapy for Multiple Myeloma

• 

  JS02-1 Cellular Therapies in Multiple Myeloma: Revolutionizing Treatment Approaches Ahmet Kursad Gunes Ankara Etlik City Hospital, Türkiye CV
• 

  JS02-2 Bispecific Antibodies in Multiple Myeloma Ja Min Byun Seoul National University College of Medicine, Korea CV

Joint Symposium 3 (EBMT-KSBMT): Recent Issues in HSCT and Cellular Therapy for ALL

• 

  JS03-1 The Role of Allogeneic Stem Cell Transplantation in Philadelphia positive ALL in the Era of Targeted Therapy Sebastian Giebel Maria Sklodowska-Curie National Research Institute of Oncology, Poland CV
• 

  JS03-2 CAR T-Cells in Pediatric Patients with B-cell Acute Lymphoblastic Leukemia Vanderson Rocha University of São Paulo, Brazil CV
• 

  JS03-3 Collaboration for the National Clinical Trials in Relapsed Pediatric and Adolescent Acute Lymphoblastic Leukemia in Korea Hyery Kim University of Ulsan College of Medicine, Korea CV
• 

  JS03-4 Treatment of Adult Acute Lymphoblastic Leukemia in Korea Han-Seung Park University of Ulsan College of Medicine, Korea CV

Joint Symposium 5 (ISCT-KSBMT): Industry-Academia Bridging in Cellular Therapy: Synergies and Challenges

• 

  JS05-1 Cell & Gene Therapy Market & CDMO Business in Korea Sun Jae Kwon ENCell Co., Ltd., Korea CV
• 

  JS05-2 AAV Vectors as the Most Popular Viral Gene Delivery System Keerang Park CdmoGen Co., Ltd., Korea CV
• 

  JS05-3 Engaging Cell & Gene Therapy Companies – A Singapore Scientist’s Experience Steve Oh Independent Cell Therapy Leader, Singapore CV

Joint Symposium 6 (JSTCT-KSBMT): Recent Updates on the Management of MDS and JMML

• 

  JS06-1 Prognostic Factors in Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Myelodysplastic Neoplasms: Retrospective Studies from a Nationwide Registry Data in Japan Hidehiro Itonaga Nagasaki University, Japan CV
• 

  JS06-2 Hematopoietic Cell Transplantation for Pediatric Myelodysplastic Syndrome in Japan: JSTCT Pediatric MDS Working Group Study Shohei Yamamoto Tokai University, Japan CV
• 

  JS06-3 Which Donor to Use for Patients with Myelodysplastic Syndrome? Joon Ho Moon Kyungpook National University School of Medicine, Korea CV
• 

  JS06-4 Characteristics and Clinical Outcomes of Juvenile Myelomonocytic Leukemia in Korea Eun Sang Yi Korea University College of Medicine, Korea CV

East Asia Collaborative Session

Current Status of CAR-T Cell Therapy: Real-World Practice and Clinical Trials

• 

  JS04-1 CAR T Therapy for Hematological Diseases in Taiwan Bor-Sheng Ko National Taiwan University Cancer Center, Taiwan CV
• 

  JS04-2 CAR T-Cell Therapy in China He Huang The First Affiliated Hospital, Zhejiang University School of Medicine, China CV
• 

  JS04-3 Current Status and Future Directions in CAR T-Cell Therapy for Lymphoma in Korea Dok Hyun Yoon University of Ulsan College of Medicine, Korea CV
• 

  JS04-4 Current Status and Challenges of CAR-T Therapy for Hematopoietic Malignancies Koji Kato Kyushu University Graduate School of Medical Sciences, Japan CV

Education Session 1: Pathogenesis, Diagnosis, Treatment of Endothelial Damage Syndrome

• 

  ES01-1 Overview of the Endothelial Dysfunction after HSCT Junshik Hong Seoul National University College of Medicine, Korea CV
• 

  ES01-2 Review of TMA Based on the Harmonized Consensus Opinion Sung Han Kang University of Ulsan College of Medicine, Korea CV
• 

  ES01-3 Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome Ka-Won Kang Korea University College of Medicine, Korea CV

Education Session 2: Conditioning Regimen in Transplant Setting

• 

  ES02-1 Conditioning Regimens: TBI and Non-TBI Regimens Jae-Ho Yoon The Catholic University of Korea, Korea CV
• 

  ES02-2 Dose Intensity for Conditioning in Allogeneic Hematopoietic Cell Transplantation: Reduced Intensity Conditioning Versus. Myeloablative Conditioning Yunsuk Choi University of Ulsan College of Medicine, Korea CV
• 

  ES02-3 Novel Conditioning Regimens for Hematopoietic Cell Transplantation Sungnam Lim Inje University College of Medicine, Korea CV

Education Session 3: Prevention and Management of Virus Disease in HSCT Patients

• 

  ES03-1 How Do I Prevent and Manage COVID-19 Infection after HSCT? Pyoeng Gyun Choe Seoul National University College of Medicine, Korea CV
• 

  ES03-2 How I Prevent and Manage CMV And Herpes Infection after HSCT? Yae-Jean Kim Sungkyunkwan University School of Medicine, Korea CV
• 

  ES03-3 How I Prevent and Manage HBV Reactivation after HSCT? Su Jong Yu Seoul National University College of Medicine, Korea CV

Education Session 4: Current and Future Direction in Chronic GVHD

• 

  ES04-1 Clinical Diagnosis and Prophylaxis of Chronic GVHD Eun-Ji Choi University of Ulsan College of Medicine, Korea CV
• 

  ES04-2 Novel Treatment and Sequence for Steroid-Refractory Chronic GVHD Eunyoung Lee National Cancer Center, Korea CV
• 

  ES04-3 Multidisciplinary Care to Improve Outcome of Chronic GVHD Seo-Yeon Ahn Chonnam National University Medical School, Korea CV

Debate Session1: Mismatched Unrelated vs. Haploidentical

• 

  DS01-1 Mismatched Unrelated Hematopoietic Stem Cell Transplantation Sung-Hoon Jung Chonnam National University Medical School, Korea CV
• 

  DS01-2 Haploidentical Jae-Cheol Jo University of Ulsan College of Medicine, Korea CV

Debate Session 2: Consolidative SCT or not after CAR T-Cell in ALL

• 

  DS02-1 The Role Consolidative HSCT Following CAR T-cell Therapy in Children and Young Adults with B-ALL Jae Won Yoo The Catholic University of Korea, Korea CV
• 

  DS02-2 Optimizing CAR-T Therapy in Pediatrics Seung min Hahn Yonsei University College of Medicine, Korea CV

Nursing Session 1: Hematology Patients Care in the Digital Era (Panel discussion)

• 

  NS01-1 Real-world data (RWD): One step closer to the truth Seunghoon Han The Catholic University of Korea, Korea CV
• 

  NS01-2 From RWD To Real-World-Evidence (RWE) in Hematologic Disease Sung-Soo Park The Catholic University of Korea, Korea CV
• 

  NS01-3 Improving Diabetes Treatment Access and Outcomes Using Integrating Technology - Diabetes Mobile Apps - Kang Hee Sim Samsung Medical Center, Korea CV
• 

  NS01-4 Introduction to Digital Therapeutics for Real-Time Symptom Monitoring and Providing Severity-Dependent Patient Advice Guiding Self Management or Medical Contact for Oncology Patients Jihyon Youn All Round Doctors, Korea CV

Nursing Session 2: Future Strategy

• 

  NS02-1 Precision Medicine in Hematologic Disease Sheehyun Kim Seoul National University College of Medicine, Korea CV
• 

  NS02-2 Clinical Experience of Covid-19 in Hematologic Patients Chang Kyung Kang Seoul National University College of Medicine, Korea CV
• 

  NS02-3 Emergency Preparedness and Response in Nursing During Unpredictable Pandemic Jae Geum Ryu Chodang University, Korea CV

Luncheon Symposium 1: Sanofi Aventis Korea

• 

  LS01 How Do I Avoid Complication of Chronic GVHD? Bipin Savani Vanderbilt University Medical Center, USA CV

Luncheon Symposium 2: BMS KOREA

• 

  LS02 Oral Azacitidine Maintenance Therapy after Intensive Chemotherapy for Transplant-Ineligible AML Patients Michael Pfeilstöcker Hanusch Hospital, Austria CV

Luncheon Symposium 3: Handok Inc.

• 

  LS03 Tafasitamab Efficacy and Safety in DLBCL Gilles Salles Memorial Sloan Kettering Cancer Center, USA CV

Luncheon Symposium 4: Gilead Science Korea Ltd.

• 

  LS04 What is Missing in Hematology? Dong-Gun Lee The Catholic University of Korea, Korea CV

Luncheon Symposium 5: MSD KOREA

• 

  LS05 CMV Prophylaxis in Letermovir Era Jeong-Ok Lee Seoul National University College of Medicine, Korea CV

Luncheon Symposium 6: Kyowa Kirin Korea

• 

  LS06 Mogamulizumab for the Treatment of MF and SS Youn H Kim Stanford University School of Medicine, USA CV

Luncheon Symposium 7: Astellas Phama Korea.Inc

• 

  LS07 Emerging Approach to Improving Treatment Outcome of FLT3 Mutated Relapsed/Refractory AML Naval Daver MD Anderson Cancer Center, USA CV

Luncheon Symposium 8: Janssen Korea

• 

  LS08 CD38 Antibodies in Multiple Myeloma: Molecular Mechanisms of Resistance Sophia Adamia Harvard Medical School / BIDMC, USA CV

Luncheon Symposium 9: Novartis Korea

• 

  LS09 Reaching for the Real-world Benefits in GvHD Corey Cutler Dana-Farber / Harvard Cancer Center, USA CV